Brind.
  1. BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company.

AscellaHealth supports rare disease manufacturers, while BioCryst Pharmaceuticals details its leadership structure with Quill, Gayer, and Oldham.

1 report, 1 independent Updated Jul 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

AscellaHealth supports rare disease manufacturers, while BioCryst Pharmaceuticals details its leadership structure with Quill, Gayer, and Oldham.

Who's involved

What this event is mainly about
BioCryst Pharmaceuticals

Keep exploring

Part of

BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies BERWYN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering cu